Radiolabeling of neurotensin agonist and antagonist with 177Lu: bioafinity of 177Lu-DOTA-NT and 177Lu-DOTA-SR48692 to neurotensin receptors

被引：1
|
作者：
Lungu, Valeria [1 ]
机构：
[1] Horia Hulbei Natl Inst Phys & Nucl Engn, Magurele, Ilfov County, Romania
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
10.1016/j.nucmedbio.2010.04.142
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：691 / 691
页数：1
相关论文
共 50 条
  • [41] Estimation of the relative biological effectiveness (RBE) of the 177Lu − DOTA − iPSMA radiopharmaceutical
    de la Fuente-Mendoza J.E.
    Azorín-Vega E.P.
    Mendoza-Nava H.J.
    Rodríguez-Martínez G.
    Rodríguez-Dorantes M.
    Applied Radiation and Isotopes, 2023, 202
  • [42] Differences on the Mechanism of Action between the Radiolabeled Somatostatin Receptor Antagonist 177Lu-OPS201 and the Agonist 177Lu-DOTA-TATE: an in vitro Investigation
    Mansi, R.
    Santoianni-Klauer, D.
    Del Pozzo, L.
    Plas, P.
    Fani, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S14 - S15
  • [43] Concomitant Dosimetry During Radionuclide Peptide Therapy with 177-Lu-DOTA-tate and 177-Lu-Lanreotide
    Heute, D. R.
    Dobrozemsky, G.
    Traub, T.
    Warwitz, B.
    von Guggenberg, E.
    Gabriel, M.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
  • [44] Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Kapusta, Waldemar
    Zmudzki, Wawrzyniec
    Mroz, Adrianna
    Kos-Kudla, Beata
    Kaminski, Grzegorz
    CANCERS, 2023, 15 (22)
  • [45] Efficacy of the personalized, dosimetry-based PRRT treatment of patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]/[90Y]Lu/Y-DOTA-TATE mixture - the DUONEN multicenter study
    Opalinska, M.
    Mikolajczak, R.
    Kaminski, G.
    Dedecjus, M.
    Kowalska, A.
    Kolodziej, M.
    Saracyn, M.
    Garnuszek, P.
    Cieszykowska, I.
    Sowa-Staszczak, A.
    Hubalewska-Dydejczyk, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S369 - S369
  • [46] Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2 -Positive Tumours
    Plas, Pascale
    Limana, Lorenzo
    Carre, Denis
    Thiongane, Amath
    Raguin, Olivier
    Mansi, Rosalba
    Meyer-Losic, Florence
    Lezmi, Stephane
    PHARMACEUTICALS, 2022, 15 (09)
  • [47] First Fully Automatized In-house Synthesis of[177Lu]Lu-DOTA-TOC in Bosnia and Herzegovina
    Stankovic, A.
    Rajkovaca, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S846 - S846
  • [48] Current Practice in Reporting Internal Dosimetry for [177Lu]Lu-DOTA-TATE Therapy: Literature Review
    Ivashchenko, O.
    O'Doherty, J.
    Perez, T.
    Tran-Gia, J.
    Hippelainen, E.
    Sandstrom, M.
    Stokke, C.
    Glatting, G.
    Cremonesi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S368 - S368
  • [49] Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
    Bergsma, Hendrik
    Konijnenberg, Mark W.
    van der Zwan, Wouter A.
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Kooij, Peter P.
    Mauff, Katya A. L.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (10) : 1802 - 1811
  • [50] Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
    Warfvinge, C. F.
    Gustafsson, J.
    Roth, D.
    Tennvall, J.
    Svensson, J.
    Bernhardt, P.
    Akesson, A.
    Wieslander, E.
    Sundlov, A.
    Gleisner, Sjogreen K.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 221 - 221
12345